Holy Grail of HCV Vaccine May Be Within Okairos' Reach
By Mari Serebrov
Thursday, March 15, 2012
While other drugmakers are spending billions of dollars in pursuit of the next-generation hepatitis C treatment, Okairos AG is on a quest for the holy grail a preventive hepatitis C virus (HCV) vaccine.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.